depression

[Xilio Therapeutics, Inc.] Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.

[Sorrento Therapeutics, Inc.] Sorrento Therapeutics, Inc. announced receipt of clearance from ANVISA to proceed with a Phase IIa randomized, placebo-controlled study of intravenous allogeneic adipose-derived MSC to treat post COVID-19 “long haul” pulmonary compromise.

[Brain Research Bulletin] Probing the possible mechanisms of neuroprotection revealed that dental pulp stem cells (DPSCs)/DPSCs-conditioned media treatment upregulated an array of hosts’ endogenous neural survival factors expression.

[Translational Oncology] The authors review previous research on the correlation between chronic stress and the occurrence and development of breast cancer, particularly the molecular mechanism through which chronic stress promotes breast cancer via neurotransmitters secreted by the nervous system.

[KetamineOne Capital Limited] KetamineOne Capital Limited announced that it is entering into a collaborative partnership with Cognetivity Neurosciences Ltd. to study and develop assessments for depression and post-traumatic stress disorder (PTSD).

[Journal of Molecular and Cellular Cardiology] Scientists tested if MSC secretome preserved myocardial transcriptome profile and whether MSC secretome from a certain source provided the optimal protection in donor hearts during cold storage.